Alzheimer’sWRAP:

The Foundation Role of
Cholinergic Dysregulation in AD

MedicineWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period April 20, 2010 through April 20, 2012 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Estimated Time to Complete Educational Activity:

Two hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of and strategies for managing Alzheimer’s disease, particularly early management with cholinesterase inhibitors.

Release Date:

April 20, 2010

Expiration Date:

April 20, 2012

Intended Audience:

• Neurologists
• Alzheimer's specialists
• Primary care physicians
• Family medicine specialists
• Internists
• Psychiatrists
• Geriatric psychiatrists
• Geriatricians
• Geriatric nurse practitioners

Registration:

Enrollment for this MedicineWRAP is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent
educational grant
from Eisai, Inc.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Jeffrey L. Cummings, MD
The Augustus S. Rose Professor of Neurology
Professor of Psychiatry and Biobehavioral Sciences
Director, Mary S. Easton Center for Alzheimer's Disease Research
Director, Deane F. Johnson Center for Neurotherapeutics
David Geffen School of Medicine at UCLA

Dr. Cummings has provided consultation to Abbott, Acadia, Accera, ADAMAS, Astellas, Avanir, Bristol-Myers Squibb, CoMentis, Eisai, Elan, EnVivo, Forest, GlaxoSmithKline, Janssen, Lilly, Lundbeck, Medivation, Merck, Merz, Myriad, Neuren, Neurokos, Novartis, Noven, Orion Pharmaceuticals, Pfizer, Prana, reMYND, Schering Plough, Signum Bioscience, Sonexa, Takeda, Toyama, and Wyeth pharmaceutical companies. He owns stock in ADAMAS, Prana, Sonexa, and Neurokos. He has been a speaker/lecturer for: Eisai, Forest, Janssen, Novartis, Pfizer, Lundbeck, Merz

Dr. Cummings owns the copyright of the Neuropsychiatric Inventory and has provided expert consultation regarding olanzapine and ropinerol.

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewers Denise Leary and Richard Aghababian, MD have nothing to disclose.

Educational Objectives:

Participants in this CME-certified MedicineWRAP will:

• Learn appropriate, guideline-consistent strategies for use of cholinesterase inhibitors in the setting of mild, moderate, and severe Alzheimer's Disease (AD)
• Learn about the role of cholinergic dysregulation and the "cholinergic hypothesis" as pathophysiological underpinnings for clinical symptoms observed in AD
• Learn how to evaluate patients with minimal and mild cognitive impairment in order to determine need for early pharmacologic intervention in AD
• Learn about landmark trials that have documented improvements in cognitive and behavioral domains that are affected in AD
• Learn about the possible mechanisms for how cholinesterase inhibitors improve cognitive function in AD
• Learn about real world approaches that employ a combination of cholinesterase inhibitors and NMDA receptor antagonists in patients with AD
  

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

• We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
• For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
• We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
• If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
• You should check this privacy policy periodically to see whether we have made any changes.
  

Disclaimer:

Copyright © 2011 Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2011 Resources, LLC All rights reserved.